Pregnancy-related venous thromboembolism

Journal of Pharmacy Practice

Volumn 27, Issue 3, 2014, Pages 243-252

  Armstrong, Emily M ^a,b   Bellone, Jessica M ^c   Hornsby, Lori B ^a,d   Treadway, Sarah ^a,b   Phillippe, Haley M ^a,e  

^a AUBURN UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^c Department of Pharmaceutical Sciences   (United States)

^d Midtown Medical Center   (United States)

^e UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

Acquired thrombophilia; Inherited thrombophilia; Pregnancy; Prophylaxis; Thrombophilia

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CESAREAN SECTION; FAMILY HISTORY; GENE MUTATION; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HOMOZYGOSITY; HUMAN; INCIDENCE; MATERNAL AGE; OBESITY; PREGNANCY; RECURRENT DISEASE; RISK ASSESSMENT; SMOKING; THROMBOPHILIA; VENOUS THROMBOEMBOLISM; COMPLICATION; FEMALE; PREGNANCY COMPLICATION; RISK FACTOR; INFERTILITY THERAPY; OVARY HYPERSTIMULATION; THROMBOSIS PREVENTION;

ANTICOAGULANTS; CESAREAN SECTION; FEMALE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MATERNAL AGE; OBESITY; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; RISK FACTORS; SMOKING; VENOUS THROMBOEMBOLISM;

EID: 84904721916     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190014530425     Document Type: Article

References (77)

1. Chunilal SD, Bates SM. Venous thromboembolism in pregnancy: diagnosis, management and prevention. Thromb Haemost. 2009; 101(3): 428-438.
2. The American College of Obstetricians and Gynecologists. Thromboembolism in pregnancy. Obstet Gynecol. 2011; 118: 718-729.
3. Calderwood CJ, Thanoon OI. Thromboembolism and thrombophilia in pregnancy. Obstet Gynaecol Reprod Med. 2009; 19: 339-343.
4. James AH. Pregnancy-Associated thrombosis. Hematology. 2009; 1: 277-285.
5. Ray JG, Chan WS. Deep vein thrombosis during pregnancy and the puerperium: a meta-Analysis of the period of risk and leg of presentation. Obstet Gynecol Surv. 1999; 54(4): 254-271.
6. Simpson EA, Lawrenson RA, Nightingale AL, et al. Venous thromboembolism during pregnancy and the peurperium: incidence and additional risk factors from a London perinatal database. Br J Obstet Gynaecol. 2001; 108(1): 56-60. (Pubitemid 32102604)
7. Gherman RB, Goodwin TM, Leung B, et al. Incidence, clinical characteristics, and timing of objectively diagnosed deep vein thromboembolism during pregnancy. Obstet Gynecol. 1999; 94(5 pt 1): 730-734. (Pubitemid 29484440)
8. Berg CJ, Callaghan WM, Syverson C, et al. Pregnancy-related mortality in the United States, 1998 to 2005. Obstet Gynecol. 2010; 116(6): 1302-1309.
9. Pomp ER, Lenselink AM, Rosendaal FR, et al. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost. 2008; 6(4): 632-637. (Pubitemid 351404930)
10. James AH, Tapson VF, Goldhaber SZ. Thrombosis during pregnancy and the postpartum period. Am J Obstet Gynecol. 2005; 193(1): 216-219. (Pubitemid 40991848)
11. Ginsberg JS, Brill-Edwards P, Burrows RF, et al. Venous thrombosis during pregnancy: leg and trimester of presentation. Thromb Haemost. 1992; 67(5): 519-520.
12. Blanco-Molina A, Trujillo-Santos J, Criado J, et al. Venous thromboembolism during pregnancy or postpartum: findings from the RIETE Registry. Thromb Haemost. 2007; 97(2): 186-190. (Pubitemid 46592137)
13. Heit JA, Kobbervig CE, James AH, et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. 2005; 143(10): 697-706.
14. Jacobsen AF, Skjeldestat FE, Sandset PM. Ante-And postnatal risk factors of venous thrombosis: a hospital-based case control study. J Thromb Haemost. 2008; 6(6): 905-912. (Pubitemid 351689910)
15. Macklon NS, Greer IA. Venous thromboembolic disease in obstetrics and gynaecology: the Scottish experience. Scott Med J. 1996; 41(3): 83-86. (Pubitemid 26232180)
16. Blondon MB, Perrier A, Nendaz M, et al. Thomboprophylaxis with low-molecular weight heparin after cesarean delivery. Thromb Haemost. 2010; 103(1): 129-137.
17. Bergqvist A, Bergqvist D, Hallbook T. Acute deep vein thrombosis (DVT) after cesarean section. Acta Obstet Gynecol Scand. 1979; 58(5): 473-476. (Pubitemid 10160484)
18. Chan LY, Lam KY, Metreweli C, et al. Duplex ultrasound screening for deep vein thrombosis in Chinese after cesarean section. Acta Obstet Gynecol Scand. 2005; 84(4): 368-370. (Pubitemid 40478186)
19. Jacobsen AF, Drolsum A, Klow NE, et al. Deep vein thrombosis after elective cesarean section. Thromb Res. 2004; 113(5): 283-288. (Pubitemid 38737368)
20. Kalro BN, Davidson RA, Owen P. Low incidence of asymptomatic deep vein thrombosis following cesarean section: a colour Doppler study. Health Bull (Edinb). 1999; 57(6): 418-421.
21. Lindqvist P, Dahlback B, Marsal K. Thrombotic risk during pregnancy: a population study. Obstet Gynecol. 1999; 94(4): 595-599. (Pubitemid 29460947)
22. Sia WW, Powrie RO, Cooper AB, et al. The incidence of deep vein thrombosis in women undergoing cesarean delivery. Thromb Res. 2009; 123(3): 550-555.
23. White RH, Brickner LA, Scannel KA. ICD-9-CM codes poorly identified venous thromboembolism during pregnancy. J Clin Epidemiol. 2004; 57(9): 985-988. (Pubitemid 39422536)
24. Pabinger I, Grafenhofer H, Kaider A, et al. Risk of pregnancyassociated recurrent venous thromboembolism in women with a history of venous thrombosis. J Thromb Haemost. 2005; 3(5): 949-954. (Pubitemid 41632825)
25. De Stefano V, Martinelli I, Rossi E, et al. The risk of recurrent venous thromboembolism in pregnancy and puerperium without antithrombotic prophylaxis. Br J Haematol. 2006; 135(3): 386-391. (Pubitemid 44484848)
26. Brill-Edwards P, Ginsberg JS, Gent M, et al. Recurrence of clot in this pregnancy study group. Safety of withholding heparin in pregnant women with a history of thromboembolism. N Engl J Med. 2000; 343(20): 1439-1444.
27. Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy. Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012; 141(2 suppl): e619s-e726s.
28. Pabinger I. Thrombophilia and its impact on pregnancy. Thromb Res. 2009; 123(suppl 3): S16-S21.
29. Robertson L, Wu O, Langhorne P, et al. Thrombophilia in pregnancy: a systemic review. Br J Haematol. 2006; 132(2): 171-196.
30. Janssen Pharmaceuticals, Inc. Xarelto1 [rivaroxaban] Tablets for Oral Use Package Insert. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2011.
31. Cutts BA, Dasgupta D, Hunt BJ. New directions in the diagnosis and treatment of pulmonary embolism during pregnancy. Am J Obstet Gyencol. 2013; 208(2): 102-108.
32. Turpie AGG, Kreutz R, Llau J, et al. Management consensus guidance for the use of rivaroxaban-An oral, direct factor Xa inhibitor. Thromb Haemost. 2012; 108(5): 876-886.
33. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood. 2005; 106(2): 401-407. (Pubitemid 40981229)
34. Tooher R, Gates S, Dowswell T, et al. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database Syst Rev. 2010; (5): CD001689.
35. Warkentin TE, Greinacher A, Koster A, et al. Heparin-induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N Engl J Med. 1995; 332: 1330-1335.
36. Ginsberg JS, Kowalchuk G, Hirsh J, et al. Heparin therapy during pregnancy. Risks to the fetus and mother. Arch Intern Med. 1989; 149(10): 2233-2236.
37. Hull RD, Delmore TJ, Carter CJ, et al. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med. 1982; 306(4): 189-194.
38. Voke J, Keidan J, Pavord S, et al. The management of antepartum venous thromboembolism in the UK and Ireland: a prospective multicenter observational survey. Br J Haematol. 2007; 139(4): 545-558. (Pubitemid 350063843)
39. Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol. 1993; 168(4): 1265-1270. (Pubitemid 23122178)
40. Petilla V, Leinonen P, Marrkova A, et al. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or low molecular weight heparin. Thromb Haemost. 2002; 87: 182-183.
41. Monreal M, Lafoz E, Olive A, et al. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost. 1994; 71(1): 7-11. (Pubitemid 24023779)
42. Carlin AG, Farquharson RG, Quenby SM, et al. Prospective and observational study of bone mineral density during pregnancy: low molecular weight heparin versus control. Hum Reprod. 2004; 19(5): 1211-1214. (Pubitemid 38618507)
43. Rodger MA, Kahn SR, Cranney A, et al. Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. J Thromb Haemost. 2007; 5(8): 1600-1606. (Pubitemid 47091398)
44. Casele J, Haney EI, James A, et al. Bone density changes in women who receive thromboprophylaxis in pregnancy. Am J Obstet Gynecol. 2006; 195(4): 1109-1113. (Pubitemid 44415673)
45. Greer IA. Thrombosis in pregnancy: updates in diagnosis and management. Hematol Am Soc Hematol Educ Prog. 2012; 2012: 203-207.
46. Nelson-Piercy C, Powrie R, Borg JV, et al. Tinzaparin use in pregnancy: an international, retrospective study of the safety and efficacy profile. Eur J Obstet Gynecol Reprod Biol. 2011; 159(2): 293-299.
47. Smith MP, Norris LA, Steer PJ, et al. Tinzaparin sodium for thrombosis treatment and prevention during pregnancy. Am J Obstet Gynecol. 2004; 190(2): 495-501. (Pubitemid 38249251)
48. Barbour LA, Oja JL, Schultz LK. A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. Am J Obstet Gynecol. 2004; 191(3): 1024-1029. (Pubitemid 39298153)
49. Jacobsen AF, Qvigstad E, Sandset PM. Low molecular weight heparin (dalteparin) for the treatment of thromboembolism in pregnancy. BJOG. 2003; 110(2): 139-144. (Pubitemid 36263109)
50. Rodie VA, Thomson AJ, Steward FM, et al. Low molecular weight heparin for the treatment of venous thromboembolism in pregnancy: a case series. BJOG. 2002; 109(9): 1020-1024. (Pubitemid 35279133)
51. Rey E, Rivard GE. Prophylaxis and treatment of thromboembolic diseases during pregnancy with dalteparin. Int J Gynaecol Obstet. 2000; 71(1): 19-24.
52. Petri M, Qazi U. Management of antiphospholipid sydnrome in pregnancy. Rheum Dis Clin North Am. 2006; 32(3): 591-607.
53. Tincani A, Bazzani C, Zinarelli S, et al. Lupus and the antiphospholipid syndrome in pregnancy and obstetrics: clinical characteristics, diagnosis, pathogenesis, and treatment. Semin Thromb Hemost. 2008; 34(3): 267-273.
54. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification of criteria for definite antiphospholipid syndrome. J Thromb Haemost. 2006; 4(2): 295-306.
55. Branch DW, Khamashta MA. Antiphospholipid syndrome: obstetric diagnosis, management, and controversies. Obstet Gynecol. 2003; 101(6): 1333-1344. (Pubitemid 36694363)
56. Oshiro BT, Silver RM, Scott JR, et al. Antiphospholipid antibodies and fetal death. Obstet Gynecol. 1996; 87(4): 489-493. (Pubitemid 26102729)
57. Empson M, Lassere M, Craig J, et al. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev. 2005; (2): CD002859. doi: 10. 1002/14651858. CD002859. pub2.
58. Kutteh W. Antiphospholipid antibody-Associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low dose aspirin alone. Am J Obstet Gynecol. 1996; 174(5): 1584-1589. (Pubitemid 26165282)
59. Rai R, Cohen H, Dave M, et al. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ. 1997; 314(7076): 253-257. (Pubitemid 27047378)
60. Mak A, Cheung MW-L, Cheak AA, et al. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive antiphospholipid antibodies: a meta-Analysis of randomized controlled trials and meta-regression. Rheumatology. 2010; 49(2): 281-288.
61. Sammaritano L. Antiphospholipid syndrome: review. South Med J. 2005; 98(6): 617-625.
62. Branch DW, Peaceman AM, Druzin M, et al. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. Am J Obstet Gynecol. 2000; 182(1 pt 1): 122-127. (Pubitemid 30074379)
63. Cowcheck FS, Reece EA, Balaban D, et al. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol. 1992; 166(5): 1318-1323.
64. Bates SM, Greer IA, Pabinger I, et al. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy. Chest. 2008; 133(6 suppl): 844s-886s.
65. Giannakopoulos B, Krilis SA. How I treat the antiphospholipid syndrome. Blood. 2009; 114: 2020-2030.
66. Nelson SM. Venous thrombosis during assisted reproduction: novel risk reduction strategies. Thromb Res. 2013; 131(suppl 1): S1-S3.
67. Rova K, Passmark H, Lindqvist PG. Venous thromboembolism in relation to in vitro fertilization: an approach to determining the incidence and increase in risk in successful cycles. Fertil Steril. 2012; 97(1): 95-100.
68. MaraM, Koryntova D, Rezabek K, et al. Thromboembolic complications in patients undergoing in vitro fertilization: retrospective clinical study [in Czech]. Ceska Gynekol. 2004; 69(4): 312-316. (Pubitemid 39062014)
69. Aurousseau MH, Samama MM, Belhassen A, et al. Risk of thromboembolism in relation to an in-vitro fertilization programme: three case reports. Hum Reprod. 1995; 10(1): 94-97.
70. Henriksson P, Westerlund E, Wallen H, et al. Incidence of pulmonary and venous thromboembolism in pregnancies after in vitro fertilization: cross sectional study. BMJ. 2013; 346: e8632.
71. Chan WS. The 'ART' of thrombosis: a review of arterial and venous thrombosis in assisted reproductive technology. Curr Opin Obstet Gynecol. 2009; 21(3): 207-218.
72. Nelson SM. Prophylaxis of VTE in women-during assisted reproductive techniques. Thromb Res. 2009; 123(suppl 3): S8-S15.
73. Grandone E, Colaizzo D, Lo Bue A, et al. Inherited thrombophilia and in vitro fertilization implantation failure. Fertil Steril. 2001; 76(1): 201-202. (Pubitemid 32600983)
74. Qublan HS, Eid SS, Ababneh HA, et al. Acquired and inherited thrombophilia: implication in recurrent IVF and embryo transfer failure. Hum Reprod. 2006; 21(10): 2694-2698. (Pubitemid 44542165)
75. Urman B, Ata B, Yakin K, et al. Luteal phase empirical low molecular weight heparin administration in patients with failed ICSI embryo transfer cycles: a randomized open-labeled pilot trial. Human Reprod. 2009; 24(7)1640-1647.
76. Allahbadia GN. Low-molecular-weight heparin (LMWH) in women with repeated implantation failure. J Obstet Gynaecol India. 2012; 62(4): 381-383.
77. Buhimschi CS, Weinger CP. Medications in pregnancy and lactation. Obstet Gynecol. 2009; 113(6): 166-188.